Literature DB >> 19956199

NUP98-HMGB3: a novel oncogenic fusion.

A Petit, C Ragu, V Della-Valle, M J Mozziconacci, M Lafage-Pochitaloff, G Soler, C Schluth, I Radford, C Ottolenghi, O A Bernard, V Penard-Lacronique, S P Romana.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19956199     DOI： 10.1038/leu.2009.241

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  20 in total

1.  Amino-terminal enhancer of split (AES) interacts with the oncoprotein NUP98-HOXA9 and enhances its transforming ability.

Authors:  Nayan J Sarma; Nabeel R Yaseen
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

Review 2.  NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights.

Authors:  Sheryl M Gough; Christopher I Slape; Peter D Aplan
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

3.  Functional analysis of the NUP98-CCDC28A fusion protein.

Authors:  Arnaud Petit; Christine Ragu; Gwendoline Soler; Chris Ottolenghi; Caroline Schluth; Isabelle Radford-Weiss; Sylvie Schneider-Maunoury; Isabelle Callebaut; Nicole Dastugue; Harry A Drabkin; Olivier A Bernard; Serge Romana; Virginie Penard-Lacronique
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

Review 4.  The role of high mobility group protein B3 (HMGB3) in tumor proliferation and drug resistance.

Authors:  Bin Wen; Ying-Ting Wei; Kui Zhao
Journal:  Mol Cell Biochem       Date:  2021-01-11       Impact factor: 3.396

5.  Upregulation of miR-513b inhibits cell proliferation, migration, and promotes apoptosis by targeting high mobility group-box 3 protein in gastric cancer.

Authors:  Xudong Chen; Guoqiang Zhao; Fuqing Wang; Fenglan Gao; Hailan Luo; Yuanyuan Wang; Yuwen Du; Xiaonan Chen; Changgui Xue; Ziming Dong; Guohua Song
Journal:  Tumour Biol       Date:  2014-08-06

6.  High mobility group-box 3 overexpression is associated with poor prognosis of resected gastric adenocarcinoma.

Authors:  Hua-Rong Tang; Xian-Qin Luo; Gang Xu; Yan Wang; Zhi-Jun Feng; Hui Xu; Ya-Wei Shi; Qin Zhang; Li-Guang Wu; Chun-Quan Xue; Cheng-Wei Wang; Chao-Yang Wu
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

7.  Overexpression of HMGB3 protein promotes cell proliferation, migration and is associated with poor prognosis in urinary bladder cancer patients.

Authors:  Minghui Li; Yong Cai; Hongmei Zhao; Zongyuan Xu; Qingsong Sun; Man Luo; Lizhi Gu; Min Meng; Xiang Han; Hong Sun
Journal:  Tumour Biol       Date:  2015-02-03

8.  In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling.

Authors:  Peter G Miller; Fatima Al-Shahrour; Kimberly A Hartwell; Lisa P Chu; Marcus Järås; Rishi V Puram; Alexandre Puissant; Kevin P Callahan; John Ashton; Marie E McConkey; Luke P Poveromo; Glenn S Cowley; Michael G Kharas; Myriam Labelle; Sebastian Shterental; Joji Fujisaki; Lev Silberstein; Gabriela Alexe; Muhammad A Al-Hajj; Christopher A Shelton; Scott A Armstrong; David E Root; David T Scadden; Richard O Hynes; Siddhartha Mukherjee; Kimberly Stegmaier; Craig T Jordan; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2013-06-13       Impact factor: 31.743

9.  Prognostic value of HMGB3 expression in patients with non-small cell lung cancer.

Authors:  Ning Song; Bao Liu; Jian-Ling Wu; Rui-Fang Zhang; Lin Duan; Wen-Shu He; Cong-Min Zhang
Journal:  Tumour Biol       Date:  2013-04-23

Review 10.  Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies.

Authors:  Nicole L Michmerhuizen; Jeffery M Klco; Charles G Mullighan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.